US20250320296
2025-10-16
Chemistry; metallurgy
C07K16/2818
The patent application discusses novel antibodies that bind to the PD-L1 protein, which is significant in the regulation of immune responses. These antibodies are designed for use in cancer treatment, particularly in cancers that express or overexpress PD-L1. The application details various methods of utilizing these antibodies to combat different types of cancer effectively.
PD-1 is a regulatory molecule on immune cells that, when engaged by its ligands PD-L1 or PD-L2, can suppress immune responses. Tumors often exploit this pathway to evade immune detection by expressing PD-L1, thereby inhibiting T-cell activity and promoting tumor growth. Targeting the PD-1/PD-L1 interaction with specific antibodies offers a promising strategy for enhancing anti-tumor immunity.
The antibodies described in the application are characterized by specific clone-paired heavy and light chain variable regions. These regions are detailed in tables within the application and can have varying degrees of sequence identity. The antibodies can be configured as single chain, chimeric, or Fab fragments and may include additional labels or therapeutic agents to enhance their efficacy.
The application outlines methods for treating PD-L1 positive cancers using these antibodies. The approach involves direct targeting of cancer cells with the antibodies, potentially in combination with other treatments such as chemotherapy or radiotherapy. This combined approach aims to improve therapeutic outcomes by simultaneously attacking cancer through multiple mechanisms.
Beyond direct cancer therapy, the antibodies have potential applications in cancer vaccines or as part of engineered cells for therapeutic purposes. The application also mentions the possibility of using genetic delivery methods to introduce these antibodies into patients, providing a versatile platform for personalized cancer treatment strategies.